Efficiency of management of patients with irritable bowel syndrome with constipation and autoimmune thyroiditis with hypothyroidism using rifaximin
Background. Irritable bowel syndrome (IBS) is a common gastrointestinal sign of gut-brain axis disorder, which occurs with abdominal pain, bloating and abnormal bowel motility, and may be divided onto subtypes: with prevalence of constipation (IBS-C), diarrhea and mixed. Autoimmune thyroiditis (AIT)...
Saved in:
| Main Author: | Yu.A. Onofrijchuk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaslavsky O.Yu.
2025-04-01
|
| Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
| Subjects: | |
| Online Access: | https://iej.zaslavsky.com.ua/index.php/journal/article/view/1502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cross‐Cohort Gut Microbiome Signatures of Irritable Bowel Syndrome Presentation and Treatment
by: Junhui Li, et al.
Published: (2024-11-01) -
Discussion of the problem of functional constipation and irritable bowel syndrome in the reports of the International Congress on Neurogastroenterology and Motility (Bologna, 2012)
by: A. A. Sheptulin, et al.
Published: (2013-03-01) -
Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
by: S. K. Zyryanov, et al.
Published: (2020-11-01) -
Microbiome in irritable bowel syndrome: advances in the field – A scoping review
by: T. Surdea-Blaga, et al.
Published: (2024-08-01) -
Bowel diseases and constipation in practice of the obstetrician and gynecologist
by: I. V. Kuznetsova, et al.
Published: (2015-03-01)